Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762 is registered in ClinicalTrials.gov with Conatus Pharmaceuticals Inc. as lead sponsor.

NCT NCT02686762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02686762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Lead sponsor
Conatus Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2016
Completion date
February 28, 2019
Enrollment
318 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, liver diseases, non-alcoholic steatohepatitis